| 标题 |
THRIVE-2 phase 3 trial of Veligrotug (VRDN-001) in chronic thyroid eye disease (TED): efficacy and safety at 15 weeks |
| 网址 | |
| DOI | |
| 其它 |
期刊:Endocrine Abstracts 作者:Patrice Rodien; Michael Schittkowski; Onur Konuk; Anja Eckstein; Adrienne Csutak; et al 出版日期:2025 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)